Stada Arzneimittel (OTCMKTS:STDAF) Rating Reiterated by DZ Bank

DZ Bank reiterated their sell rating on shares of Stada Arzneimittel (OTCMKTS:STDAF) in a report issued on Wednesday, December 20th.

Shares of Stada Arzneimittel (STDAF) remained flat at $$100.50 during trading hours on Wednesday. The company has a market capitalization of $6,726.70, a P/E ratio of 61.28 and a beta of -1.76. Stada Arzneimittel has a 52 week low of $51.40 and a 52 week high of $100.50.

TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with's FREE daily email newsletter.

Leave a Reply